Enterprise Innovation Forum awards China Sky One Medical's CEO "Leadership Excellence in Innovation"

NewsGuard 100/100 Score

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that Mr. Yan-Qing Liu, the Company's Chairman and Chief Executive Officer, received the award for "Leadership Excellence in Innovation" from the organizing committee of China Enterprise Innovation Forum.

Mr. Liu will attend the 10th China Enterprise Innovation Forum and the award ceremony held in Beijing on June 6, 2010. The Enterprise Innovation Forum is sponsored by a number of industry associations, including the Chinese Association for Productivity & Science, which was established under the approval of China's Ministry of Civil Affairs in 1980. There will be over 500 attendees including senior government officials, economists, business leaders as well as journalists. Each year in China, this award is presented to up to 50 business leaders who have demonstrated leadership in driving innovation at their companies and generating considerable economic benefits.

"I accept this honor on behalf of all the employees at China Sky One Medical who have helped to drive the Company's innovative advances over the years. We will continue our focus on developing and commercializing novel medical technologies and drugs to help physicians and patients, and create long term value for our shareholders," said Mr. Liu.

Source:

China Sky One Medical, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk